Editing Linezolid (section)

====Infections of the central nervous system====
In animal studies of [[meningitis]] caused by ''Streptococcus pneumoniae'', linezolid was found to penetrate well into [[cerebrospinal fluid]], but its effectiveness was inferior to that of other antibiotics.<ref name=Moellering/><ref>{{cite journal |vauthors=Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Täuber MG |title=Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model |journal=Journal of Antimicrobial Chemotherapy |volume=46 |issue=6 |pages=981–5 |date=December 2000 |pmid=11102418 |doi=10.1093/jac/46.6.981|doi-access=free }}</ref> There does not appear to be enough high-quality evidence to support the routine use of linezolid to treat bacterial meningitis. Nonetheless, it has been used successfully in many cases of [[central nervous system]] infection—including meningitis—caused by susceptible bacteria, and has also been suggested as a reasonable choice for this indication when treatment options are limited or when other antibiotics have failed.<ref name=Sabbatani/><ref>{{cite journal |vauthors=Ntziora F, Falagas ME |title=Linezolid for the treatment of patients with central nervous system infection |journal=Annals of Pharmacotherapy |volume=41 |issue=2 |pages=296–308 |date=February 2007 |pmid=17284501 |doi=10.1345/aph.1H307 |s2cid=33514115 |issn=1060-0280}} Structured abstract with quality assessment available at [http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007005296 DARE] {{webarchive|url=https://web.archive.org/web/20110902114025/http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007005296 |date=2 September 2011 }}.</ref> The guidelines of the Infectious Diseases Society of America recommend linezolid as the first-line drug of choice for VRE meningitis, and as an alternative to vancomycin for MRSA meningitis.<ref>{{cite journal  |vauthors=Tunkel AR, Hartman BJ, Kaplan SL, etal |title=Practice guidelines for the management of bacterial meningitis |journal=Clinical Infectious Diseases |volume=39 |issue=9 |pages=1267–84 |date=November 2004 |pmid=15494903 |doi=10.1086/425368 |issn=1058-4838|doi-access=free }}</ref> Linezolid appears superior to vancomycin in treating community-acquired MRSA infections of the central nervous system, although very few cases of such infections have been published ({{as of|2009|lc=on}}).<ref name=Naesens>{{cite journal |vauthors=Naesens R, Ronsyn M, Druwé P, Denis O, Ieven M, Jeurissen A |title=Central nervous system invasion by community-acquired methicillin-resistant ''Staphylococcus aureus'': case report and review of the literature |journal=[[Journal of Medical Microbiology]] |volume= 58|issue= Pt 9|pages= 1247–51|date=June 2009 |pmid=19528145 |doi=10.1099/jmm.0.011130-0 |issn=0022-2615}}</ref>